EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and Immunogenicity of Meningococcal Serogroup B Vaccine (4CMenB) and 13-Valent Pneumococcal Vaccine Administered Concomitantly with Routine Infant Vaccines to Healthy United States Infants: A Randomized, Controlled Clinical Study

Debasish Saha, Laura Tomasi Cont, Nicola P Klein, Judith M Martin, Elisa Cinconze, Pavitra Keshavan, Luca Moraschini, Danielle Morelle, Mauro Trapani, Maria Lattanzi, Daniela Toneatto, James Campbell und 26 weitere

Open Forum Infectious Diseases · 06.11.2026

DOI: 10.1093/ofid/ofag709 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 06.11.2026. Verfasst von Debasish Saha und 37 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Meningococcal serogroup B (MenB) vaccine, 4CMenB, has been licensed in the United States (US) since 2015 for individuals aged 10–25 years. This study assessed 4CMenB in US infants when administered concomitantly with pneumococcal vaccine PCV13 and other routine infant vaccines (RIVs).

Methods

This phase 3b, observer-blind, placebo-controlled study (NCT03621670) randomized (2:1) healthy US infants to receive either 4CMenB administered concomitantly with PCV13 and other RIVs (N=786; 4CMenB+RIVs group) or placebo with PCV13 and other RIVs (N=409; Placebo+RIVs group) at 2, 4, 6, and 12 months of age. Primary objectives were to demonstrate the sufficiency of immune responses to MenB indicator strains (individually and combined), to demonstrate the non-inferiority of immune responses to PCV13 administered with 4CMenB+RIVs versus PCV13 plus placebo+RIVs, and assess safety. Immune responses to RIVs administered with 4CMenB+PCV13 versus RIVs plus placebo+PCV13 were investigated as secondary objectives.

Results

Pre-specified sufficiency criteria post-dose 3 and post-dose 4 were met for each MenB strain except NHBA and the composite response. Percentages of seroprotected participants (human serum bactericidal assay titers ≥lower limit of quantitation) against MenB indicator strains post-dose 4 were 86.1–99.6% in 4CMenB+RIVs group versus 0.0–2.8% in Placebo+RIVs group. The success criterion for achieving immunological non-inferiority of PCV13 was met, and concomitant 4CMenB administration did not adversely affect immune responses to other RIVs. 4CMenB co-administered with PCV13 and RIVs was generally well tolerated, with no safety concerns identified.

Conclusions

4CMenB was well tolerated and immunogenic in US infants, producing no immunological interference when co-administered with other recommended vaccines.

Zitieren

APA

Saha, D., Cont, L. T., Klein, N. P., Martin, J. M., Cinconze, E., Keshavan, P., Moraschini, L., Morelle, D., Trapani, M., Lattanzi, M., Toneatto, D., Campbell, J., Clifford, R., Hartvickson, R., Hughes, T., Klein, N. P., Kulshrestha, A., Leonardi, M., Marshall, G., …, & Kumar, A. K. (2026). Safety and Immunogenicity of Meningococcal Serogroup B Vaccine (4CMenB) and 13-Valent Pneumococcal Vaccine Administered Concomitantly with Routine Infant Vaccines to Healthy United States Infants: A Randomized, Controlled Clinical Study. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofag709

Vancouver

Saha D, Cont LT, Klein NP, Martin JM, Cinconze E, Keshavan P, et al. Safety and Immunogenicity of Meningococcal Serogroup B Vaccine (4CMenB) and 13-Valent Pneumococcal Vaccine Administered Concomitantly with Routine Infant Vaccines to Healthy United States Infants: A Randomized, Controlled Clinical Study. Open Forum Infectious Diseases. 2026. doi:10.1093/ofid/ofag709

BibTeX
@article{Saha2026,
  author = {Saha, Debasish and Cont, Laura Tomasi and Klein, Nicola P and Martin, Judith M and Cinconze, Elisa and Keshavan, Pavitra and Moraschini, Luca and Morelle, Danielle and Trapani, Mauro and Lattanzi, Maria and Toneatto, Daniela and Campbell, James and Clifford, Robert and Hartvickson, Robyn and Hughes, Teena and Klein, Nicola P and Kulshrestha, Aarti and Leonardi, Michael and Marshall, Gary and Martin, Judith M and Moore, Michael and Peltier, Christopher and Rok, Walter and Schumacher, Randall and Senders, Shelly and Weiner, Leonard and Cinconze, Elisa and Toneatto, Daniela and Keshavan, Pavitra and Lattanzi, Maria and Moraschini, Luca and Morelle, Danielle and Saha, Debasish and Cont, Laura Tomasi and Trapani, Mauro and Bollu, Yamini Purna and Yarraguntla, Aparna and Kumar, and Keshaw},
  title = {Safety and Immunogenicity of Meningococcal Serogroup B Vaccine (4CMenB) and 13-Valent Pneumococcal Vaccine Administered Concomitantly with Routine Infant Vaccines to Healthy United States Infants: A Randomized, Controlled Clinical Study},
  journal = {Open Forum Infectious Diseases},
  year = {2026},
  doi = {10.1093/ofid/ofag709}
}
Kostenlos starten →